Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial

INTRODUCTION: Ivermectin is an antiparasitic drug which has in-vitro efficacy in reducing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral load. Hence, Ivermectin is under investigation as a repurposed agent for treating COVID-19. METHODS: In this pilot, double blind, randomized co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Anant, Tiwari, Pawan, Suri, Tejas Menon, Mittal, Saurabh, Patel, Ankit, Jain, Avinash, Velpandian, Thirumurthy, Das, Ujjalkumar Subhash, Boppana, Tarun Krishna, Pandey, Ravindra Mohan, Shelke, Sushil Suresh, Singh, Angel Rajan, Bhatnagar, Sushma, Masih, Shet, Mahajan, Shelly, Dwivedi, Tanima, Sahoo, Biswajeet, Pandit, Anuja, Bhopale, Shweta, Vig, Saurabh, Gupta, Ritu, Madan, Karan, Hadda, Vijay, Gupta, Nishkarsh, Garg, Rakesh, Meena, Ved Prakash, Guleria, Randeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384587/
https://www.ncbi.nlm.nih.gov/pubmed/34483029
http://dx.doi.org/10.1016/j.jiac.2021.08.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384587/
https://www.ncbi.nlm.nih.gov/pubmed/34483029
http://dx.doi.org/10.1016/j.jiac.2021.08.021

Ejemplares similares